Some important context to actually evaluate the benefits, from the published article [1]: - Only five patients were enrolled, median age 56 years. - One of th

Some important context to actually evaluate the benefits, from the published article [1]: - Only five patients were enrolled, median age 56 years. - One of them died, so 20% mortality in the study group. We can't conclude anything from such a small sample size, of course. - No causal link can be established at this stage between viral burden and clinical improvement, nor between treatment and viral burden. In other words, this is just a study to check that UVA light can be further studied without killing patients left and right, and apparently it can. It isn't able to draw conclusions about the efficacy of the treatment. 1: https://link.springer.com/article/10.1007/s12325-021-01830-7 https://link.springer.com/article/10.1007/s12325-021-01830-7